Table 1.

Patient and disease characteristics of prostate cancer patients treated with chemohormonal therapy (CHP) and radical prostatectomy (RP) vs those eligible for enrollment but underwent RP only. CHT patients were also compared to a high-risk RP subset of the comparison group at the top 30% of the Kattan risk score. Data presented are median (IQR) or frequency (%).

	CHT + RP (n=34)	RP Only (n=123)	p-value	High Risk RP (N=37)	p-value
Clinical Risk Factors
Age at diagnosis	56.0 (51.0, 61.0)	60.8 (55.5, 64.9)	0.002	57.6 (55.0, 62.7)	0.2
Total PSA	27.7 (11.0, 43.2)	9.2 (5.5, 20.0)	<0.0001	16.8 (10.1, 23.0)	0.017
Predicted 5-year risk of BCR*	69.1 (54.5, 90.2)	36.2 (25.2, 50.9)	<0.0001	68.1 (52.1, 72.2)	0.091
Clinical Stage
T1c/T2a	12 (35%)	66 (54%)	<0.0001	6 (16%)	0.002
T2b/T2c	4 (9%)	42 (34%)		17 (46%)
T3a/T3b	18 (53%)	15 (12%)		14 (38%)
Biopsy Gleason Score
<7	2 (6%)	16 (13%)	0.005	4 (11%)	0.7
7	17 (53%)	27 (22%)		21 (57%)
>=8	14 (41%)	80 (65%)		12 (32%)
Pathologic Outcomes
Extracapsular Extension	34 (100%)	70 (57%)		25 (68%)
Seminal Vesicle Invasion	20 (59%)	31 (25%)		14 (38%)
Bladder Neck Invasion	8 (24%)	10 (8.1%)		6 (16%)
Positive Surgical Margins	8 (24%)	47 (38%)		17 (46%)
Positive Nodes	2 (5.9%)	16 (13%)		8 (22%)
Pathological stage
T2a	2 (5.9%)	10 (8.1%)		1 (2.7%)
T2b/T2c	9 (26%)	39 (32%)		8 (22%)
T3a/T3b	16 (47%)	64 (52%)		22 (59%)
T4	7 (21%)	10 (8.1%)		6 (16%)
Pathologic Gleason Score
Not graded due to CHT	23 (68%)	0		0
6	1 (9.1%)	8 (6.5%)		2 (5.4%)
7	4 (36%)	62 (50%)		20 (54%)
8	1 (9.1%)	28 (23%)		7 (19%)
9	5 (45%)	25 (20%)		8 (22%)
Postoperative Treatment
Adjuvant Treatment	3 (9.1%)	1 (1.7%)		1 (5.9%)
Salvage XRT within 5 years	3 (8.8%)	26 (21%)		5 (14%)

^*Based on the Kattan Nomogram (Gleason grade, clinical stage and PSA)